Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imricor Medical SystemsASX:IMR -2.06%39 Days Sales Outstanding is 1,840.21 as of Jun. 2026, which is 1307% above its 10-year median of 130.80. GuruFocus rates ASX:IMR with a GF Score™ of 39/100 and a GF Value™ of A$0.16 (Significantly Overvalued). The stock has 11 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Imricor Medical Systems ranks worse than 98.64% on this metric.
The historical rank and industry rank for Imricor Medical Systems's Days Sales Outstanding or its related term are showing as below:
ASX:IMR'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.3 Med: 130.8 Max: 759.91
Current: 759.91
During the past 8 years, Imricor Medical Systems's highest Days Sales Outstanding was 759.91. The lowest was 48.30. And the median was 130.80.
ASX:IMR's Days Sales Outstanding is ranked worse than 98.64% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.38
vs ASX:IMR: 759.91
Imricor Medical Systems's Days Sales Outstanding
increased
from Jun. 2025 (282.18) to Jun. 2026 (1,840.21).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Imricor Medical Systems (ASX:IMR) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Imricor Medical Systems Days Sales Outstanding Related Terms
Imricor Medical Systems Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Imricor Medical Systems's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems Days Sales Outstanding Chart
ASX:IMR vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Imricor Medical Systems's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's Days Sales Outstanding falls into.
Imricor Medical Systems Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 1,840.21 mean?
Imricor Medical Systems (ASX:IMR) has a Days Sales Outstanding of 1,840.21 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Imricor Medical Systems and its competitors. This is 1307% above median its historical median of 130.80. Over the past decade, Imricor Medical Systems' Days Sales Outstanding has ranged from 48.30 to 759.91. According to the industry distribution chart, Imricor Medical Systems ranks #799 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 98.6%.
Is Imricor Medical Systems' Days Sales Outstanding too high?
Imricor Medical Systems' current Days Sales Outstanding of 1,840.21 is 1307% above median its 10-year median of 130.80. Over the past 10 years, this metric has ranged from a low of 48.30 to a high of 759.91. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.38. Imricor Medical Systems' value of 1,840.21 is 2714.6% above this industry median. Based on the distribution chart, Imricor Medical Systems ranks #799 out of 810 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #799 out of 810 companies for Days Sales Outstanding. This places Imricor Medical Systems in the lower half of its industry. The industry median Days Sales Outstanding is 65.38. Imricor Medical Systems' value of 1,840.21 is 2714.6% above this benchmark. Historically, Imricor Medical Systems' own Days Sales Outstanding has ranged from 48.30 to 759.91 over the past decade. While the company's 10-year median is 130.80 vs. the industry median of 65.38, Imricor Medical Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.38, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imricor Medical Systems's current Days Sales Outstanding of 1,840.21 is 2714.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Imricor Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current Days Sales Outstanding is 1,840.21, which is 1307% above median its own 10-year median of 130.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.16, compared to a current price of A$1.91 — trading 1090.6% above its estimated fair value. The current Days Sales Outstanding is 1,840.21, which is 1307% above median its 10-year median of 130.80 and 2714.6% above the Medical Devices & Instruments industry median of 65.38. Imricor Medical Systems' overall GF Score™ is 39/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Days Sales Outstanding is 1,840.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.91 is trading 1090.6% above its estimated GF Value™ of A$0.16.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
Days Sales Outstanding: 1,840.21 (1307% above median its 10-year median of 130.80)
GF Value™: A$0.16 vs. price of A$1.91 (1090.6% above fair value)
Industry Position: 2714.6% above the Medical Devices & Instruments median (#799 of 810)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
39GF Score
Get the complete analysis for ASX:IMR
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
